<DOC>
	<DOCNO>NCT01760304</DOCNO>
	<brief_summary>To investigate whether Budesonide/Formoterol ( Symbicort ® ) therapy improve heart function rest decrease lung hyperinflation patient COPD ( Chronic Obstructive Pulmonary Disease ) .</brief_summary>
	<brief_title>Changes Cardiac Function COPD Patients After Administration Budesonide/Formoterol ( Symbicort® ) Versus Placebo</brief_title>
	<detailed_description>Patients moderate advanced COPD know static hyperinflation ( rest ) consequence expiratory flow limitation . Hyperinflation easily detect measure lung volume standard pulmonary function test . Decreased Inspiratory Capacity ( IC ) secondary hyperinflation describe predictor mortality COPD , limit factor maximal tidal volume attain exercise . Hyperinflation link low cardiac output part limit leave ventricular ejection fraction exercise . Treatment inhale anticholinergic agent long-acting beta agonist ( LABA ) combination LABA formoterol budesonide show improve IC decrease lung hyperinflation . Bronchodilators show improve exercise endurance COPD combine pulmonary rehabilitation , however exact mechanism : improvement lung mechanic /or improvement cardiac function well know . Impedance cardiography ( ICG ) emerge method measure cardiac output without need invasive device . Cardiac output measurement impedance cardiography ( CO-ICG ) valid reproducible method . It show good correlation thermodilution direct Fick method measurement stroke volume cardiac output . In addition , oxygen pulse , easily obtain dividing measure oxygen uptake heart rate ( VO2/HR ) provide adequate reflection cardiac stroke volume systemic extraction oxygen stable . This method use evaluate effect static dynamic hyperinflation cardiac function . This pilot study design single center ( Brigham Women 's Hospital ) , randomize , placebo-controlled , double blind , crossover study 14 patient ( male female 40 80 year old ) COPD static hyperinflation . The primary endpoint measurement stroke volume , cardiac output oxygen pulse rest administration budesonide/formoterol compare placebo .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Outpatients subject either sex age 4080 year , diagnosis COPD . COPD characterize presence airflow obstruction FEV1/FVC &lt; 0.7 ( Forced Expiratory Volume one second / Forced Vital Capacity ) FEV1 &lt; 80 % predict . All patient must lung hyperinflation demonstrate increase ≥100 ml administration budesonide/formoterol . All patient must cigarette smoke history 10 packyears , able perform specify procedure require protocol . 1 . Patients significant disease ( recent &lt; 6 week COPD exacerbation ) could place patient risk participation study , may influence result study patient ' ability participate study . 2 . All patient recent ( &lt; 1 year ) history myocardial infarction , recent history heart failure ( NYHA class III IV , pulmonary edema , patient cardiac arrhythmia . 3 . Patients daytime oxygen therapy . 4 . Patients know active tuberculosis . 5 . Patients history active cancer except nonmetastatic skin cancer . 6 . Patients undergone thoracotomy , sternotomy , major cardiopulmonary intervention ( lung resection , open heart surgery , etc ) , procedure 6 month prior evaluation likely cause instability pulmonary status . 7 . Patients upper respiratory infection past six week .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>COPD</keyword>
</DOC>